Dapagliflozin for heart failure according to body mass index: the DELIVER trial

Overview of attention for article published in European Heart Journal, August 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

So far, Altmetric has seen 335 X posts from 254 X users, with an upper bound of 911,992 followers.

BMIに基づく心不全に対するダパグリフロジン：DELIVER試験 Dapagliflozin for heart failure according to body mass index: the DELIVER trial https://t.co/91HOC9EJgP

RT @ESC_Journals: Dapagliflozin for heart failure according to body mass index: the DELIVER trial https://t.co/7fnz8vEwOs @escardio #EHJ…

RT @ehj_ed: Dapagliflozin for heart failure according to body mass index: the DELIVER trial. Read more about the efficacy and safety of new…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 331 additional X posts.